Cytori Therapeutics, Inc. (USA) (NASDAQ:CYTX)

CAPS Rating: 2 out of 5

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions.

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar egustafson58 (< 20) Submitted: 8/6/2014 9:59:06 AM : Outperform Start Price: $1.64 CYTX Score: -18.72

It hit bottom.. it has to go up right..??????

Recs

0
Member Avatar BillStacker (< 20) Submitted: 7/3/2013 9:07:52 PM : Outperform Start Price: $2.38 CYTX Score: -63.97

Made a good move with the new loan to sustain them for a while. I think the stock has bottomed and is ready to rebound.

Recs

0
Member Avatar vxfrbeva (< 20) Submitted: 2/3/2012 3:20:29 PM : Outperform Start Price: $4.20 CYTX Score: -115.15

Cytori Therapeutics is inmerse in a big moment right now. Their bussines is going to get huge as there is a big market for the stem cells applied to heart recovery after heart atacks and also for the breasts surgery.

Recs

0
Member Avatar englishdk (< 20) Submitted: 12/7/2011 7:50:24 AM : Underperform Start Price: $2.57 CYTX Score: +104.06

stem cells dont work

Recs

0
Member Avatar wayne094 (< 20) Submitted: 11/16/2011 2:24:31 PM : Outperform Start Price: $2.75 CYTX Score: -107.32

more and more horse trainers and pro sport players arre looking into stem cell its a rocket about to take off.

Recs

0
Member Avatar mrindependent (86.39) Submitted: 7/19/2011 5:57:10 PM : Outperform Start Price: $4.92 CYTX Score: -121.47

This company has exciting technology and is selling near the low end of its range.

Recs

0
Member Avatar durango58 (< 20) Submitted: 3/24/2011 4:46:58 PM : Outperform Start Price: $7.95 CYTX Score: -134.40

Strong patent portfolio and the razor/razor blade business model. I've been long for two years and it's paying off.

Recs

0
Member Avatar Zangeith15 (25.89) Submitted: 11/16/2010 12:17:23 AM : Outperform Start Price: $4.77 CYTX Score: -137.89

Great stem cell research company that has great potential.

Recs

0
Member Avatar TBraymanJr (< 20) Submitted: 8/30/2010 5:44:13 PM : Outperform Start Price: $4.60 CYTX Score: -159.71

Compared to other stem cell technologies, deriving the stem cells from from liposuction is the least controversial and invasive, with significant benefits still attainable. It is not a panacea, but it has its applicability.

Recs

0
Member Avatar pcolajoe (30.78) Submitted: 8/15/2010 11:31:03 AM : Outperform Start Price: $4.40 CYTX Score: -153.64

They extract stem cells from the patient, and can build tissue with it. Cutting edge technology.

Recs

0
Member Avatar Willodjw (< 20) Submitted: 4/29/2010 4:53:48 AM : Outperform Start Price: $5.48 CYTX Score: -140.56

cytx

Recs

0
Member Avatar redskins66 (< 20) Submitted: 3/24/2010 10:26:21 AM : Outperform Start Price: $4.83 CYTX Score: -141.37

cause fools say it won't

Recs

0
Member Avatar kvmfan (< 20) Submitted: 3/15/2010 10:23:33 AM : Outperform Start Price: $5.13 CYTX Score: -145.89

This is still a very promising stock for the future, and after being severely punished this week it will certainly start to increase again.

Recs

1
Member Avatar JGGardner (< 20) Submitted: 2/17/2010 2:00:16 PM : Outperform Start Price: $7.60 CYTX Score: -162.86

The Regenerative Medicine market is expected to grow to $3 billion by 2015. Cytori Therapeutics (CYTX) is the early leader in this market and is now treating, on a daily basis, more patients than any competing stem cell company. Given the large patent portfolio, existing approval in 42 countries, pending US FDA approval, partnerships with GE and Olympus, and high margin business model we expect Cytori to maintain its leadership position with sales approaching $1 billion over the next 5 years. With a similar growth pattern Intuitive Surgical (ISRG) carried a $10 billion valuation when it was at the same sales level. We expect the leader in the faster growing regenerative medicine market to carry an equal or greater market cap. Expect US FDA approval to be the key catalyst over the next 12 months.

Recs

4
Member Avatar InvestorHowe (< 20) Submitted: 2/3/2010 11:15:16 PM : Outperform Start Price: $7.59 CYTX Score: -164.62

Cytori is bursting with potential. Between their groundbreaking treatments with the celution machine, their pending FDA approval in the U.S., multiple clinical studies, established markets in Europe and Japan, corporate partnerships with GE and Olympus, multiple patents, and visionary managment, Cytori is well positioned to not only participate in new stem cell markets but dominate them. This stock is just getting started, and should have a wild ride up over the next five years.

Recs

1
Member Avatar jekoslosky (46.18) Submitted: 1/29/2010 10:38:23 PM : Outperform Start Price: $6.74 CYTX Score: -163.69

This one was due a sharp plunge after an unrealistic run-up. Still, I like it longer-term, with its PureGraft product hitting the market, and other products in the pipeline. PureGraft, a consumable that offers the company a high profit margin, should be a cash generator. Keeping my shares and seeing what kind of cash the company can generate.

Recs

1
Member Avatar d0319a (< 20) Submitted: 1/29/2010 9:55:54 AM : Outperform Start Price: $3.61 CYTX Score: -147.60

Why do shaving cream companies allmost give away their razors? Because they get you on the blades! This is what Cytori is all about. Every time they have a procedure you must reorder the consumables, and that is where the money is.
Companies like GE would not partner with them if there was not a significnt profit potential for them.

The big golden ring, besides breast augmentation,etc. is the future for the heart tests. If it is true that these stem cells can grow back heart function then this is one of the most important advances in medical history.

Recs

0
Member Avatar Rick1961 (< 20) Submitted: 1/15/2010 10:50:06 AM : Outperform Start Price: $8.08 CYTX Score: -158.09

Up 313% from initial purchase. This company still has a long way to go.

Recs

0
Member Avatar turnmore1 (< 20) Submitted: 12/28/2009 7:54:58 AM : Outperform Start Price: $6.04 CYTX Score: -153.53

I grabbed this description from the Fool:
A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions.

I Think this is good. Health is Wealth.

Recs

0
Member Avatar mikehelin (< 20) Submitted: 9/22/2009 11:03:58 AM : Outperform Start Price: $3.78 CYTX Score: -149.43

Their stem cell concentration system has demonstrated sucess for reconstructive and cosmetic surgical proceedures and it appears to be effective in cardiac tissue repair.
Could be a huge winner

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners


Advertisement